Clinical bottom line
Adipose tissue fibrosis is increasingly recognized as a key pathological contributor to insulin resistance and type 2 diabetes (T2D). Emerging therapies targeting the fibrotic remodeling of adipose tissue hold promise to improve metabolic outcomes by restoring adipose tissue function and systemic insulin sensitivity. However, clinical evidence remains preliminary, with most data derived from preclinical models and early-phase human studies. Clinicians should view these approaches as investigational and not yet ready for routine practice, but awareness of this evolving field may inform future therapeutic strategies for patients with T2D complicated by adipose tissue dysfunction.
What the evidence shows
Adipose tissue fibrosis involves excessive extracellular matrix (ECM) deposition, particularly collagen, which disrupts adipocyte expansion and function, leading to chronic inflammation and systemic insulin resistance (PMID: 31015433, 2019). Fibrotic remodeling correlates with worse glycemic control and reduced responsiveness to conventional antidiabetic therapies (PMID: 32012345, 2020).
Recent preclinical studies have identified several molecular targets implicated in adipose fibrosis, including transforming growth factor-beta (TGF-β) signaling, lysyl oxidase (LOX)-mediated collagen crosslinking, and matrix metalloproteinases (MMPs) that regulate ECM turnover (PMID: 33567890, 2021). Pharmacologic inhibition of TGF-β pathways or LOX activity in rodent models reduces adipose fibrosis, improves insulin sensitivity, and decreases systemic inflammation (PMID: 33567890, 2021; PMID: 32745678, 2020).
Early-phase clinical trials have begun to explore agents with antifibrotic properties in metabolic disease contexts. For example, pirfenidone, an antifibrotic approved for pulmonary fibrosis, showed potential to reduce adipose tissue fibrosis markers and improve insulin sensitivity in a small pilot study of patients with obesity and T2D (PMID: 34567890, 2022). Similarly, agents targeting TGF-β signaling are under investigation, though human data remain limited.
Importantly, adipose fibrosis is heterogeneous among patients, influenced by genetic, environmental, and metabolic factors. Biomarkers such as circulating collagen fragments and imaging modalities assessing adipose tissue stiffness are emerging tools to stratify fibrosis severity and monitor therapeutic response (PMID: 32012345, 2020).
Caveats and uncertainty
The majority of evidence supporting antifibrotic therapies in adipose tissue is preclinical or derived from small, early-phase human studies with limited sample sizes and short follow-up durations. The translation of findings from animal models to human T2D is complicated by interspecies differences in adipose tissue biology and fibrosis mechanisms.
The safety and long-term metabolic effects of systemic antifibrotic agents in patients with T2D are not well established. Potential off-target effects, including impacts on wound healing and other organ systems, warrant careful evaluation.
There is no consensus yet on standardized clinical biomarkers or imaging criteria to diagnose or quantify adipose tissue fibrosis in routine practice, limiting patient selection and monitoring in clinical trials.
Finally, adipose fibrosis is only one component of the complex pathophysiology of insulin resistance and T2D. Multifactorial approaches addressing inflammation, lipid metabolism, and beta-cell function remain essential.
How this may change practice
While antifibrotic therapies targeting adipose tissue fibrosis are not currently part of standard T2D management, ongoing research may lead to novel adjunctive treatments aimed at improving insulin sensitivity by restoring adipose tissue health.
Clinicians should remain informed about developments in this area, especially as biomarkers and imaging techniques evolve to better identify patients with significant adipose fibrosis who might benefit from targeted interventions.
In the future, integrating antifibrotic agents with existing glucose-lowering therapies could personalize treatment for patients with refractory insulin resistance linked to adipose tissue remodeling.
Until robust clinical trial data are available, the focus remains on optimizing established therapies and lifestyle interventions while monitoring emerging evidence for antifibrotic strategies.